P4A Let's Talk Rare: The Life Science Podcast

The episode surfaces a handful of real data points (6–9% clinical trial access rate, 4–5 year diagnostic odyssey) and names relevant technologies, but the bulk of the conversation is high-level acknowledgement of well-known problems—fragmentation, data silos, AI as enabler—without unpacking mechanisms or sharing actionable takeaways a rare-disease operator couldn't find in any white paper.

“it's maybe 6% of patients get into clinical trials. I've heard it may be as high as 9%, but really, on average, I mean, that's shocking, right?”

“The technology is really only as good as the data that we put into it.”

Almost every point made—fragmentation, need for connected ecosystems, AI as a tool not a panacea, patient voice importance—is standard rare-disease industry discourse with no contrarian angle, first-principles reasoning, or genuinely counterintuitive claim throughout the episode.

“I feel like it's table stakes to be able to use technology in that way.”

“it's not really about the technology per se, or that trials need to be done differently. It's fundamentally more about creating a more connected, basically ecosystem healthcare system.”

Dr. Carter is a genuine practitioner with impressive credentials—co-founded one of the first molecular oncology decision-support companies (N of 1) in 2008, sold it, worked as a VC at a Blue Cross Blue Shield venture arm, and is now building MedZone—but the interview never extracts the depth of operator knowledge her background should yield.

“back in 2008, I started one of the first personalized medicine or precision medicine companies called N of 1. And we started the field of what today is known as molecular oncology decision support.”

“I was a managing partner at Blue Venture Fund and Sandbox Industries, which is a venture firm for Blue Cross Blue Shield.”

There are some named diseases (SMA, Duchenne's, hemophilia, sickle cell) and a couple of rough statistics, but MedZone's own results are never quantified, no specific trials or payers are named, and the mechanistic claims about how their platform works remain entirely vague.

“Look at sma, right? Look at Duchenne's, look at hemophilia, right? And sickle cell now, right. I mean, the progress is massive, right?”

“about 25% of all cancer is rare”

The hosts spend a material portion of the 34-minute episode on icebreaker either/or questions (pets, sweet vs. savory, Formula One simulators) and consistently lob open, unprobing questions; there is no pushback, no request for specifics on MedZone's outcomes, and no productive disagreement anywhere in the transcript.

“So sweet or savory?”

“Tell us a bit more about what you do at medzone.”